Market Overview

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aegerion Pharmaceuticals, Inc. (AEGR)

Share:

NEW YORK, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq: AEGR) in the United States District Court for the District of Massachusetts on behalf of current stock holders of Aegerion, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act").

On June 14, 2016, Aegerion's Board of Directors (the "Board") caused the Company to enter into an agreement and plan of merger (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of Parent common stock. The Complaint alleges that on August 8, 2016, Defendants issued materially incomplete and misleading disclosures in the Form S-4 Registration Statement (the "Registration Statement") filed with the United States Securities and Exchange Commission ("SEC") in connection with the Proposed Transaction. The Registration Statement is deficient and misleading in that it fails to provide adequate disclosure of all material information related to the Proposed Transaction.

If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.

Please visit our website at http://www.gme-law.com for more information about the firm.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com